Arc Labs

Arc Labs, the Antimicrobial Regeneration Consortium, develops an innovative framework to accelerate research and development of countermeasures against evolving pathogens, focusing on antimicrobial resistance. It builds an ecosystem for medical technology development, bridging academic discoveries with industrial scale-up. The organization utilizes a sustainable innovation model to advance novel therapeutics and diagnostics.

Founded by Assistant Professors Anushree Chatterjee and Prashant Nagpal around 2020, Arc Labs originated from the insight that the traditional drug discovery pipeline is too slow and inefficient for rapidly mutating bacteria and viruses. Their academic backgrounds highlighted the urgent need for a dynamic approach to develop treatments for global health challenges.

The organization empowers academic researchers and the pharmaceutical industry by incubating technologies, facilitating their spin-out into viable startups. Its vision is to disrupt the archaic drug discovery process, ensuring timely development and delivery of effective medicine for emergent infectious diseases, ultimately enhancing global healthcare accessibility.